कंपनी का अवलोकन
Pluri Inc. is a biotechnology firm dedicated to the research, development, and manufacturing of cell-based products, cell therapeutics, and associated technologies tailored for multiple industries. The company specifically focuses on creating placenta-based cell therapy product candidates intended to treat conditions such as inflammatory diseases, muscle injuries, and other medical issues. This enterprise operates within the Healthcare sector and the Biotechnology industry, where innovation in cellular medicine drives the creation of novel treatments for complex physiological challenges. The company's market capitalization stands at $32.56M, while its trailing twelve-month revenue is reported at $1.34M, supported by a workforce of 127 employees. These financial figures indicate that Pluri Inc. is a small-cap entity with limited revenue generation relative to its operational scope, suggesting it remains in a growth or development phase rather than a mature profit-generating stage within the competitive biotechnology landscape.
वित्तीय स्वास्थ्य
The company reported a revenue of $1.34M over the trailing twelve months, yet it recorded a net income of $-26,138,000, highlighting a significant structural gap where costs substantially exceed earnings before tax and interest. The EBITDA for the period was $-24,435,000, further emphasizing the heavy operational burn rate typical of early-stage biotechnology research and development activities. Free cash flow stands at $-14,348,750, which indicates that the company is currently utilizing cash reserves to fund operations and research rather than generating liquidity from its core business activities. The gross margin is recorded at 40.6%, reflecting the cost structure of manufacturing cell-based products, while the operating margin is a negative 3285.9% and profit margin is 0.0%, illustrating severe operational inefficiencies or high overhead costs relative to the minimal revenue base. In terms of liquidity, the company holds $12.48M in cash against a total debt load of $34.94M, resulting in a debt-to-equity ratio that is listed as N/A, implying a highly leveraged balance sheet relative to its equity base. The current ratio is 0.43, which signals a potential liquidity constraint as current liabilities exceed current assets, indicating difficulty in meeting short-term obligations without external financing or asset sales. Return on Equity is N/A due to the lack of positive retained earnings impacting equity, while Return on Assets is -50.6%, revealing that the asset base is generating negative returns for the period under review.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A because the company is not currently profitable, whereas the forward P/E is -1.71, a metric that reflects negative expected earnings in the near future rather than a traditional valuation multiple based on past performance. The price-to-book ratio is -2.21, which indicates that the market is valuing the company at a negative multiple of its book value, a common characteristic for biotechnology firms with significant intangible assets or pending clinical trials that have not yet translated into equity value. Alternative valuation metrics include a price-to-sales ratio of 24.32 and an EV/EBITDA of -2.47, suggesting that investors are pricing the stock based on future growth potential in cell therapy rather than current profitability or asset backing. The stock's price range over the last 52 weeks spans from a low of $2.82 to a high of $7.13, providing a historical context for price volatility within the healthcare sector. Without a specific current price provided in the available facts to calculate the exact percentage deviation from the 52-week high, the trading range demonstrates significant fluctuation typical of small-cap biotechnology stocks with high beta risk. The beta value is 0.73, which implies that the stock's price volatility is lower than the broader market, moving with 73% of the market's intensity despite its high-risk nature.
Growth & Income
Revenue growth year-over-year is recorded at 7.0%, while earnings growth is N/A due to the company's consistent net losses, indicating that top-line expansion is occurring without immediate translation into profitability. Since the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that any available earnings would theoretically be reinvested into research and development, though in this case, the company is burning cash rather than distributing income. The absence of a dividend program and the negative earnings growth underscore the strategy of prioritizing capital expenditure for product development over shareholder income distribution. The overall growth and income profile for Pluri Inc. is characterized by modest top-line expansion coupled with substantial financial losses and no current income generation for shareholders.